company background image
RLF logo

Relief Therapeutics Holding SWX:RLF Stock Report

Last Price

CHF1.38

Market Cap

CHF17.3m

7D

3.6%

1Y

-82.0%

Updated

26 Mar, 2024

Data

Company Financials

Relief Therapeutics Holding SA

SWX:RLF Stock Report

Market Cap: CHF17.3m

RLF Stock Overview

Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.

RLF fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Relief Therapeutics Holding SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Relief Therapeutics Holding
Historical stock prices
Current Share PriceCHF1.38
52 Week HighCHF15.00
52 Week LowCHF1.30
Beta-14.37
1 Month Change-13.75%
3 Month Change-25.41%
1 Year Change-82.03%
3 Year Change-98.85%
5 Year Change-38.39%
Change since IPO-93.10%

Recent News & Updates

Recent updates

Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

May 05
Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt?

Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Oct 04
Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Apr 23
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

Sep 25
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry?

We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

Jan 13
We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide

Shareholder Returns

RLFCH BiotechsCH Market
7D3.6%16.4%0.9%
1Y-82.0%-1.1%4.2%

Return vs Industry: RLF underperformed the Swiss Biotechs industry which returned -5.7% over the past year.

Return vs Market: RLF underperformed the Swiss Market which returned 4.3% over the past year.

Price Volatility

Is RLF's price volatile compared to industry and market?
RLF volatility
RLF Average Weekly Movement6.4%
Biotechs Industry Average Movement7.4%
Market Average Movement3.4%
10% most volatile stocks in CH Market7.7%
10% least volatile stocks in CH Market1.8%

Stable Share Price: RLF's share price has been volatile over the past 3 months.

Volatility Over Time: RLF's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
201369Michelle Lockhttps://www.relieftherapeutics.com

Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.

Relief Therapeutics Holding SA Fundamentals Summary

How do Relief Therapeutics Holding's earnings and revenue compare to its market cap?
RLF fundamental statistics
Market capCHF17.31m
Earnings (TTM)-CHF80.79m
Revenue (TTM)CHF5.86m

3.0x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RLF income statement (TTM)
RevenueCHF5.86m
Cost of RevenueCHF1.45m
Gross ProfitCHF4.41m
Other ExpensesCHF85.20m
Earnings-CHF80.79m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-6.44
Gross Margin75.26%
Net Profit Margin-1,378.18%
Debt/Equity Ratio1.8%

How did RLF perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.